Structure Therapeutics Inc - American Depositary Shares — Filings & Documents (NASDAQ:GPCR) — Page 6 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2022

Annual report, Q4 FY2022

Structure Therapeutics Inc. annual report, Q4 FY2022

1
2
3
4
5
6

News

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term (SEPN)